← Back to all signals
RESEARCH PAPER ANALYSIS

What Are the Long-term Outcomes of Wrist Arthrodesis Using Structural Iliac Bone Graft After Resection of the Distal Radius for Giant Cell Tumor of Bone? A Minimum 10-year Follow-up.

AI interpretation is pending for this paper.

Open original publication →
PMID41237399
JournalClinical orthopaedics and related research
Publication Date2025-11-04
Ingested2026-08-02 12:05 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: Most distal radial giant cell tumors are treated with curettage, whereas malignancies and very advanced giant cell tumor of bone (GCTB) may be treated with resection. Wide resection can achieve good local control, but no consensus has been obtained on the optimal reconstruction method. The use of an endoprosthetic wrist arthroplasty offers the advantage of wrist motion. However, it is associated with a high risk of wrist subluxation, pain, and compensation limitations; ultimately, some patients undergo wrist arthrodesis. We previously reported good early outcomes using wrist arthrodesis and structural iliac bone graft for bone defects after wide resection of the distal radius GCTB. This study evaluates the long-term function, complications, and risk factors of this reconstruction technique at > 10 years of follow-up. QUESTIONS/PURPOSES: (1) What were the 5-year and 10-year overall graft survival and revision-free survival rates? (2) What proportion of patients achieved bone union by 6 and 12 months? (3) What were the functional outcomes of patients at final follow-up? (4) What were the overall proportions of patients who experienced complications and complications leading to reoperation and its possible risk factors? METHODS: After approval by our institutional review board, we performed a retrospective study of patients who underwent wrist arthrodesis and structural iliac bone graft reconstruction after wide resection of distal radius primary bone tumors and who had at least 10 years of follow-up, using our institutional database (Jishuitan Sarcoma database) undergoing prospective maintenance by Beijing Jishuitan Hospital. Between January 2005 and January 2025, we treated 231 patients for distal radius GCTB. Of those, we considered patients with Campanacci III GCTB as potentially eligible. Twenty-three percent (53 of 231) of patients underwent curettage. Based on that, 77% (178 of 231) of patients were eligible. Ten percent (18 of 178) were excluded because they received other reconstruction methods, including vascularized fibular graft and massive allografts. Nine percent (16 of 178) of patients who were lost to follow-up were excluded. Forty-five percent (80 of 178) of patients who had < 10 years of follow-up and 36% (64) of patients were included for survivorship and complication analyses here. Of patients who had > 10 years of follow-up, fifty-six percent (36 of 64) were men. The mean ± SD age was 31 ± 11 years. The indication for reconstruction was resection of Campanacci Grade III GCTB. Patient outcomes included overall graft survival, revision-free survival, functional scores (Musculoskeletal Tumor Society Score-93 [MSTS-93], DASH, and Patient-Rated Wrist Evaluation [PRWE] scores), wrist stability (Carpal Translation Index), and grip strength. All complications were classified as major complications and minor complications. A major complication was defined as a complication resulting in an unplanned reoperation. Graft survival rates were calculated by Kaplan-Meier methods. RESULTS: The 5-year and 10-year overall graft survival rates for all 144 patients (including > 10-year and ≤ 10-year follow-up) were 98% (95% confidence interval [CI] 80% to 99%) and 98% (95% CI 80% to 99%), respectively. The 2-year, 5-year, and 10-year revision-free survival rates were 90% (95% CI 83% to 94%), 78% (95% CI 69% to 83%), and 76% (95% CI 60% to 81%), respectively. For patients who had > 10 years of follow-up, sixty-one percent (39 of 64) of grafts achieved union within 6 months, 84% (54 of 64) united within 12 months, and 16% (10 of 64) did not unite. The mean ± SD MSTS-93 score was 95% ± 5% (range 0% to 100%, with higher scores indicating better function), the mean DASH score was 13 ± 5 (range 0 to 100, with lower scores indicating better function), and the mean PRWE score was 18 ± 6 (range 0 to 100, with lower scores indicating better function). Thirty-five percent (51 of 144) of patients had at least one complication. During follow-up, 28% (41 of 144) of patients underwent 51 reoperations because of major complications. After controlling for potentially confounding variables such as gender, age, and previous surgery, we found that the use of reconstruction plates for fixation (cause-specific HR 2.2 [95% CI 1.3 to 12]; p = 0.02) and bone nonunion (cause-specific HR 2.7 [95% CI 2.1 to 7.2]; p = 0.03) were associated with an increased risk of plate fractures. The use of reconstruction plates (cause-specific HR 2.3 [95% CI 1.4 to 2.9]; p = 0.04) and autograft > 8 cm (cause-specific HR 1.7 [95% CI 1.1 to 3.3]; p = 0.03) was associated with an increased risk of bone nonunion. CONCLUSION: Resection followed by wrist arthrodesis and structural iliac bone graft for distal radius GCTB achieved satisfactory oncologic and functional results, albeit with one-third of all patients experiencing some complications at a minimum of 10 years of follow-up. Although wrist arthrodesis sacrificed wrist mobility, making it an option to consider after extensive resection of the distal radius, we cannot compare this with other reconstruction options. Functional outcomes and complications must be investigated further in large prospective studies. LEVEL OF EVIDENCE: Level III, therapeutic study.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Comparison of Phenol Application and Endoscopic Pilonidal Sinus Treatment in Pediatric Pilonidal Sinus Disease. Pediatrics international : official journal of the Japan Pediatric Society 63.74 2 Unfinished Business and Experiences of Bereaved Families of Patients with Cancer: A Cross-Sectional Survey. Palliative medicine reports 61.0 3 The 21st International ``Ponte di Legno'' Childhood Acute Lymphoblastic Leukemia Workshop Report: Progress and Emerging Opportunities. Clinical lymphoma, myeloma & leukemia 49.0 4 Acute Leukemia During the First Six Months of Life: A Population-Based Analysis of Survival by Leukemia Type. Clinical lymphoma, myeloma & leukemia 64.12 5 Pediatric orbital solitary fibrous tumor/hemangiopericytoma presenting with isolated eyelid edema: a case report. Frontiers in pediatrics 53.1 6 Malignancies in patients with inborn errors of immunity: insights from 20-years of clinical experience in Qatar. Frontiers in immunology 68.6 7 Precision medicine and parental experience: a longitudinal study of psychosocial responses to germline genomic results in pediatric oncology. Frontiers in medicine 67.36 8 Cytokine-augmented risk stratification for six-month incident nephritis in children with IgA vasculitis. Frontiers in pediatrics 58.5 9 Time-bounded uncertainty in childhood cancer survivorship: a psycho-oncology perspective on result communication. Frontiers in psychology 57.0 10 "From misdiagnosis to precision medicine: strengthening pediatric neuro-oncology care in LMICs toward equitable pLGG outcomes". Frontiers in oncology 75.5 11 Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper. European journal of neurology 66.4 12 Technical Considerations for Robotic Pediatric Lobectomy. Annals of thoracic surgery short reports 54.0 13 Kaposi Sarcoma-Associated Herpesvirus Is Not Detected in Osteosarcoma From KSHV-Endemic African Countries and the Non-Endemic United States Populations. Journal of medical virology 59.5 14 ELISA (Embedding-Linked Interactive Single-cell Agent): an interpretable hybrid generative Artificial Intelligence agent for expression-grounded discovery in single-cell genomics. Briefings in bioinformatics 48.5 15 Thyroid Cancer in the Modern Era: From Molecular Landscape and Multimodal Diagnostics to Integrative Traditional Chinese Medicine-A Comprehensive Review. Cancer management and research 90.6 16 Presumed left atrial myxoma presenting with seizures, massive stroke, and systemic embolization in an adolescent: a case report. International journal of emergency medicine 49.0 17 Ewing's Sarcoma in Adults: A Predictive Nomogram and Survival Analysis of a Cohort of 937 Patients. Journal of surgical oncology 73.92 18 Comments on "Initial Cerebrospinal Fluid Blast Clearance Rate in Pediatric B-Lymphoblastic Leukemia Is Associated With Overall Survival". Journal of pediatric hematology/oncology 49.12 19 Impact of Number of Lymph Nodes Sampled and Density of Positive Nodes on Outcomes Among Over 2000 Patients With Stage I to III Favorable Histology Wilms Tumor Enrolled on AREN03B2: A Children's Oncology Group Renal Tumor Study. Annals of surgery 70.5 20 Prognostic impact of risk organ involvement and metabolic parameters assessed by staging 18F-FDG PET/CT in pediatric Langerhans cell histiocytosis. Nuclear medicine communications 63.3 21 Prognostic value of plasma thymus- and activationregulated chemokine levels after the second cycle of chemotherapy in pediatric Hodgkin lymphoma. Haematologica 55.44 22 Germline lymphoma-predisposing variants: impact on age of cancer diagnosis and survival in pediatric patients. Haematologica 51.12 23 Excess mortality convergence after paediatric allogeneic transplantation: a caveat for the right to be forgotten. Comment on: "Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia". Haematologica 49.5 24 EARLY DISCONTINUATION OF ANTIBIOTICS IN PEDIATRIC PATIENTS WITH LOW- AND HIGH-RISK FEBRILE NEUTROPENIA: A SINGLE-CENTRE EXPERIENCE. Journal of the Pediatric Infectious Diseases Society 68.4 25 Comment on "How I Approach Anxiety in Children and Teens with Cancer". Pediatric blood & cancer 47.5 26 Progressive Tracheal Injury Following Tumor Regression in a Child With T-Cell Lymphoblastic Lymphoma. Pediatric blood & cancer 28.5 27 Very Late Relapse of Acute Myeloid Leukemia With a Rare HNRNPH1::MLLT10 Fusion Following a Pediatric Myeloid Neoplasm: A Successful Venetoclax-Azacitidine Bridge to Hematopoietic Stem Cell Transplantation. Pediatric blood & cancer 49.12 28 Interventions to Reduce Financial Toxicity of Childhood, Adolescent, and Young Adult Cancer Survivors: A Scoping Review. Pediatric blood & cancer 61.32 29 ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T-Cell Lymphoblastic Leukemia/Lymphoma. Pediatric blood & cancer 87.42 30 Advanced Radiotherapy Across a Multi-Geography Referral Network for Children With Ewing Sarcoma and Rhabdomyosarcoma: Treatment Delivery and Early Outcomes-A Single-Centre Experience. Pediatric blood & cancer 72.88 31 Genomic Characterization of ETV6::RUNX1-Positive Childhood B-ALL in a Chinese Cohort: Novel Fusion Partners, Co-Occurring Mutations, and Risk-Stratifying Biomarkers. Pediatric blood & cancer 59.75 32 Diagnostic Yield of Brain MRI in Pediatric Short Stature: Hypothalamic-Pituitary Lesions and Incidental Findings in Real-World Practice. Clinical endocrinology 67.3
PATIENT-FRIENDLY SUMMARY

What Are the Long-term Outcomes of Wrist Arthrodesis Using Structural Iliac Bone Graft After Resection of the Distal Radius for Giant Cell Tumor of Bone? A Minimum 10-year Follow-up.

For education only—not personal medical advice.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic